VAERS Table of Reportable Events Following Vaccination*	
Vaccine/Toxoid	**Event and interval from vaccination**
Tetanus in any combination; DTaP, DTP, DTP-Hib, DT, Td, TT, Tdap, DTaP-IPV, DTaP-IPV/Hib, DTaP-HepB-IPV	A. Anaphylaxis or anaphylactic shock (7 days) B. Brachial neuritis (28 days) C. Any acute complications or sequelae (including death) of above events (interval - not applicable) D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Pertussis in any combination; DTaP, DTP, DTP-Hib, Tdap, P, DTaP-IPV, DTaP-IPV/Hib, DTaP-HepB-IPV	A. Anaphylaxis or anaphylactic shock (7 days) B. Encephalopathy or encephalitis (7 days) C. Any acute complications or sequelae (including death) of above events (interval - not applicable) D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Measles, mumps and rubella in any combination; MMR, MR, M, MMRV, R	A. Anaphylaxis or anaphylactic shock (7 days) B. Encephalopathy or encephalitis (15 days) C. Any acute complications or sequelae (including death) of above events (interval - not applicable) D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Rubella in any combination; MMR, MMRV, MR, R	A. Chronic arthritis (42 days) B. Any acute complications or sequelae (including death) of above event (interval - not applicable) C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Measles in any combination; MMR, MMRV, MR, M	A. Thrombocytopenic purpura (7-30 days) B. Vaccine-strain measles viral infection in an immunodeficient recipient (6 months) C. Any acute complications or sequelae (including death) of above events (interval - not applicable) D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Oral Polio (OPV)	A. Paralytic polio ○ in a non-immunodeficient recipient (30 days) ○ in an immunodeficient recipient (6 months) ○ in a vaccine-associated community case (interval - not applicable) B. Vaccine-strain polio viral infection ○ in a non-immunodeficient recipient (30 days) ○ in an immunodeficient recipient (6 months)

VAERS Table of Reportable Events Following Vaccination*	
Vaccine/Toxoid	**Event and interval from vaccination**
	○ in a vaccine-associated community case (interval - not applicable) C. Any acute complication or sequelae (including death) of above events (interval - not applicable) D. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Inactivated Polio -IPV, DTaP-IPV, DTaP-IPV/HIB, DTaP-HepB-IPV	A. Anaphylaxis or anaphylactic shock (7 days) B. Any acute complication or sequelae (including death) of the above event (interval - not applicable) C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Hepatitis B in any combination- HepB, HepA-HepB, DTaP-HepB-IPV, Hib-HepB	A. Anaphylaxis or anaphylactic shock (7 days) B. Any acute complications or sequelae (including death) of the above event (interval - not applicable) C. Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Hemophilus influenzae type b in any combination (conjugate)- Hib, Hib-HepB, DTP-Hib, DTaP-IPV/Hib	Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Varicella in any combination- VAR, MMRV	Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Rotavirus (monovalent or pentavalent) RV1, RV5	Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Pneumococcal conjugate (7-valent or 13-valent) PCV7, PCV13	Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Hepatitis A in any combination- HepA, HepA-HepB	Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Influenza--trivalent inactivated influenza , live	Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)

VAERS Table of Reportable Events Following Vaccination*	
Vaccine/Toxoid	**Event and interval from vaccination**
attenuated influenza-TIV, LAIV	
Meningococcal - MCV4, MPSV4	Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)
Human Papillomavirus (Quadrivalent or Bivalent)-HPV4, HPV2	Events described in manufacturer's package insert as contraindications to additional doses of vaccine (interval - see package insert)

* Effective date: November 10, 2008. The Reportable Events Table (RET) reflects what is reportable by law (42 USC 300aa-25) to the Vaccine Adverse Event Reporting System (VAERS) including conditions found in the manufacturers package insert. In addition, healthcare professionals are encouraged to report any clinically significant or unexpected events (even if you are not certain the vaccine caused the event) for any vaccine, whether or not it is listed on the RET. Manufacturers are also required by regulation (21CFR 600.80) to report to the VAERS program all adverse events made known to them for any vaccine.

A list of vaccine abbreviations is attached and is also located at:
http://www.cdc.gov/vaccines/recs/acip/vac-abbrev.htm

Vaccine	Abbreviation*
Diphtheria and tetanus toxoids adsorbed (children)	DT
Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed	DTaP
Diphtheria and tetanus toxoids and whole cell pertussis vaccine	DTP
Diphtheria and tetanus toxoids and whole cell pertussis vaccine and *Haemophilus influenzae* type b conjugate vaccine	DTP-Hib
Tetanus and diphtheria toxoids adsorbed (adult)	Td
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Tdap
Tetanus toxoid	TT
Diphtheria and tetanus toxoids and acellular pertussis adsorbed and *Haemophilus influenzae* type b conjugate vaccine	DTaP/Hib
Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B and inactivated poliovirus vaccine	DTaP-HepB-IPV
Diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	DTaP-IPV
Diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and *Haemophilus influenzae* type b conjugate vaccine	DTaP-IPV/Hib
Haemophilus influenzae type b conjugate vaccine	Hib
Haemophilus influenzae type b conjugate and hepatitis B vaccine	Hib-HepB
Hepatitis A vaccine	HepA
Hepatitis B vaccine	HepB
Hepatitis A inactivated and hepatitis B vaccine	HepA-HepB
Human papillomavirus vaccine (quadrivalent)	HPV4
Human papillomavirus vaccine (bivalent)	HPV2
Trivalent inactivated influenza vaccine	TIV
Live attenuated influenza vaccine	LAIV
Measles vaccine	M
Measles and rubella vaccine	MR
Measles, mumps, and rubella vaccine	MMR
Measles, mumps, rubella, and varicella vaccine	MMRV

Meningococcal conjugate vaccine (quadrivalent)	MCV4
Meningococcal polysaccharide vaccine (quadrivalent)	MPSV4
Pertussis	P
Pneumococcal conjugate vaccine (7-valent)	PCV7
Pneumococcal conjugate vaccine (13-valent)	PCV13
Poliovirus vaccine (inactivated)	IPV
Poliovirus vaccine (live)	OPV
Rubella vaccine	R
Rotavirus vaccine (monovalent)	RV1
Rotavirus vaccine (pentavalent)	RV5
Varicella vaccine	VAR

*dash (-) indicates: products that are supplied in their final form by the manufacturer and do not require mixing or reconstitution by user; slash (/) indicates: products that are mixed or reconstituted by user.